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a  b  s  t  r  a  c  t
The  brain  pathology  in autism  spectrum  disorders  (ASD)  indicates  marked  and ongoing  inﬂammatory
reactivity  with  concomitant  neuronal  damage.  These  ﬁndings  are  suggestive  of neuronal  insult  as  a  result
of external  factors,  rather  than  some  type  of  developmental  mishap.  Various  xenobiotics  have  been  sug-
gested  as possible  causes  of this  pathology.  In a recent  review,  the top  ten  environmental  compounds
suspected  of causing  autism  and  learning  disabilities  were listed and  they  included:  lead,  methyl-
mercury,  polychorinated  biphenyls,  organophosphate  pesticides,  organochlorine  pesticides,  endocrine
disruptors,  automotive  exhaust,  polycyclic  aromatic  hydrocarbons,  polybrominated  diphenyl  ethers,  and
perﬂuorinated  compounds.  This  current  review,  however,  will focus  speciﬁcally  on  mercury  exposure
and  ASD  by  conducting  a comprehensive  literature  search  of original  studies  in  humans  that  examineelationship the  potential  relationship  between  mercury  and  ASD,  categorizing,  summarizing,  and  discussing  the
published  research  that  addresses  this  topic.  This review  found  91  studies  that  examine  the  potential
relationship  between  mercury  and  ASD  from  1999  to February  2016.  Of these  studies,  the  vast  major-
ity  (74%)  suggest  that  mercury  is  a risk  factor  for  ASD,  revealing  both  direct  and indirect  effects.  The
preponderance  of the  evidence  indicates  that mercury  exposure  is  causal  and/or  contributory  in ASD.
©  2016  The  Author(s).  Published  by Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Autism spectrum disorders (ASD) is deﬁned by persistent
eﬁcits in social communication and social interaction, and
estricted, repetitive patterns of behavior, interests, or activities
1]. Although an ASD diagnosis is deﬁned behaviorally by the Amer-
can Psychiatric Association, other features, more physical or health
elated, are associated with an ASD diagnosis.
ASD is considered to be heritable with complex inheritance and
enetic heterogeneity [2]; however, a consensus is emerging that
he total fraction of ASD attributable to genetic inheritance may
nly be 30–40% [3]. Chromosomal microarray testing reveals that
pproximately 80% of children with ASD have a normal genome
4]. Of the remaining 20%, approximately half of those have vari-
us polymorphisms of unknown signiﬁcance and the other half of
hose have de novo mutations with little or no commonality. These
ndings suggest that non-genetic factors have a signiﬁcant role in
he etiology of ASD.
In addition, many brain pathology studies indicate marked and
ngoing neuroinﬂammation in ASD [5–14]. This type of reactive
athology is suggestive of insult and with concomitant neuronal
amage [15] rather than some type of developmental mishap as
as been suggested [16,17]. A developmental mishap does not
xplain the evidence of neuroinﬂammatory reactivity and neu-
onal damage within the brain in ASD which includes: (1) activated
icroglia (immune macrophages within the brain); (2) activated
strocytes (a broad class of cells that support neurons within the
rain); (3) elevated levels of glial ﬁbrillary acidic protein (GFAP;
n intermediate ﬁlament protein that is expressed by astrocytes
ossibly to maintain structural integrity, known to be upregulated
n response to injury); (4) increased oxidative stress (e.g., elevated
eurotrophin-3, elevated 3-nitrotyrosine, and oxidized glutathione
evels, etc.); (5) elevated levels of 8-oxo-guanosine (a product of
xidative damage to DNA); (6) elevated proinﬂammatory cytokines
e.g., tumor necrosis factor alpha, interleukin 6, and granulocyte-
acrophage colony-stimulating factor); (7) aberrant expression of
uclear factor kappa-light-chain-enhancer of activated B cells (NF-
B, a protein complex that regulates transcription and reﬂects the
ellular response to stress); and (8) neuronal cell loss [8,15,18–21].
or does it explain the classic regression found in autism that
ccurs around 15–22 months of age where these children lose pre-
iously acquired neurological function, such as language and other
nteractive skills and abilities [22].
Various xenobiotics have been suggested as causal agents in the
athology of ASD. In a highly-cited review, Grandjean and Lan-
rigan [23] identiﬁed ﬁve industrial chemicals as developmental
eurotoxicants based on epidemiological evidence: lead, methyl-
ercury, polychlorinated biphenyls, arsenic, and toluene. In an
nvironmental Health Perspectives editorial, Landrigan et al. [3]
ote that neurodevelopmental disabilities affect over 10% of chil-
ren born in the US each year and listed the top ten environmental
ompounds suspected of causing autism and learning disabilities:
ead, methylmercury, polychorinated biphenyls, organophosphate
esticides, organochlorine pesticides, endocrine disruptors such as . . . . . . . . . . .  . . .  . . . . .  . . . . .  . . . . .  . . .  .  . . . .  . . .  . . .  . .  . .  .  . . . .  . . .  .  .  .  . . . .  .  . . . . .  . . . . .  . . . 21
phthalates, automotive exhaust, polycyclic aromatic hydrocarbons,
polybrominated diphenyl ethers (brominated ﬂame retardants),
and perﬂuorinated compounds. Both teams specify “methylmer-
cury” rather than the broader class “mercury”, possibly because
more studies exist on the methylmercury form (found in ﬁsh), and
possibly because ethylmercury (found in Thimerosal-containing
vaccines) and mercury vapor (released from dental amalgams) are
unpopular targets.
Of the numerous studies that have been conducted over the
last three decades that examine the relationship between mercury
exposure and ASD, the majority of the studies found that mercury
is a risk factor for ASD. However, there are also several studies that
suggest mercury is not a risk factor for ASD, therefore evaluating
the totality of the evidence is not easy.
This review will focus on mercury exposure and ASD by conduct-
ing a comprehensive literature search of original studies in humans
that examine the potential relationship between mercury and ASD
from 1999 to February 2016, including studies of human tissue
levels of mercury, studies of biomarkers for mercury exposure,
and epidemiological studies. The literature search includes pub-
lished original research studies on mercury and ASD, from PubMed
and Google Scholar; however, references cited in identiﬁed pub-
lications were also searched to locate additional studies. Search
words included: autism, autism spectrum disorders, ASD, pervasive
developmental disorders, PDD, mercury, Hg, Thimerosal, metals,
methyl-mercury, ethyl-mercury, inorganic-Hg, mercury chloride.
This review will categorize, summarize, and discuss the pub-
lished research that addresses this topic. Each section of this paper
will present an area of scientiﬁc inquiry on the issue and the studies
which have been published on it. An associated table(s) in each sec-
tion will brieﬂy describe the pertinent studies and their ﬁndings.
This review will begin with studies that examine brain biomarkers
and mercury levels in children with ASD.
2. Brain biomarkers and mercury levels in children with
ASD
Many studies show production of numerous auto-antibodies
which react with speciﬁc brain proteins and brain tissues in chil-
dren with ASD. These auto-antibodies can also act to alter the
function of the respective brain tissue [24]. In addition, studies
show that anti-brain antibodies are associated with more severe
cognitive and behavioral proﬁles in children with ASD [25]. More-
over, recent studies (see Table 1 ) have found that certain brain
auto-antibodies correlate with mercury levels in children with ASD
[26,27].
This ﬁnding is biologically plausible since studies show that
mercury exposure, especially to the mercury-based compound
Thimerosal, can cause autoimmune dysfunction. For example,
Voldani et al. [28] conducted a study that demonstrated cer-
tain dietary peptides, bacterial toxins, and xenobiotics, such
as Thimerosal, can bind to lymphocyte receptors and/or tis-
sue enzymes, resulting in autoimmune reaction in children with
autism. Havarinasab et al. [29] also found that Thimerosal can
induce (in genetically susceptible mice) a systemic autoimmune
syndrome.
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Table 1
Studies that show brain biomarkers correlate with mercury levels in children with ASD.
Biomarker Authors and Journal N Age Purpose of Study Findings
Brain Tissue
Autoantibodies
(antineuronal antibodies)
Mostafa and Al-Ayadhi [26]
Egypt. J. Pediatr. Allergy
Immunol.
ASD 40
Controls 40
3–8 y
Serum antineuronal
antibodies and blood
mercury levels were
estimated between autism
and controls
Higher seropositivity for
antineuronal antibodies and
higher blood mercury in autism
vs. controls. Seropositivity of
antineuronal antibodies had
positive association with
elevated blood mercury (found
in 70% of autistic children).
Both markers positively
associated with behavioral
abnormalities, autistic
regression, EEG abnormalities
Brain  Tissue
Autoantibodies
(anti-MBP auto-antibodies)
Mostafa and Refai [27]
Clin. Cell. Immunol.
ASD 50
Controls 30
5–12 y
Blood mercury levels and
seropositivity of anti-MBP
autoantibodies in autistic
children
Serum levels of blood mercury
were signiﬁcantly higher in
autistic children than healthy
controls; increased levels of
blood mercury were found in
48% of autistic patients, and
72% of autistic children had
anti-MBP auto-antibodies.
There was a signiﬁcant positive
association between the
elevated levels of blood
mercury and anti-MBP
auto-antibodies in autistic
children.
Brain  Neuropeptides in
Serum
Mostafa et al. [30]
Metab. Brain Dis.
ASD 84
Controls 84
3–10 y
Examined
pro-inﬂammatory
neuropeptides and
mercury in serum
signiﬁcant and positive linear
relationship between levels of
serum neurokinin A and blood
mercury in moderate and
severe ASD, but not controls
Brain  Oxidative Stress –
3-NT
Sajdel-Sulkowska et al. [31]
Am.  J. Biochem. Biotechnol.
ASD 9
Controls 10
5–37 y
Oxidative stress marker
3-NT, mercury, and the
antioxidant selenium in
autism and controls
Signiﬁcant increases in the
mean cerebellar levels of 3-NT
and in the ratio of
mercury/selenium in the
brains of subjects diagnosed
with autism when compared to
controls; there was a
signiﬁcant dose-dependent
positive correlation between
oxidative stress markers and
A trotyr
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d
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i
l
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T
a
(
c
e
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f
i
tSD = autism spectrum disorders; anti-MBP = anti myelin basic protein; 3-NT = 3-ni
In a recent study, Mostafa et al. [30] found a signiﬁcant and pos-
tive linear relationship between levels of serum neurokinin A (a
ro-inﬂammatory neuropeptide) and blood mercury levels in chil-
ren with moderate and severe ASD, but not in healthy control
hildren. They found that 78.3 % of the children with ASD with
ncreased serum levels of neurokinin A had elevated blood mercury
evels.
In addition, Sajdel-Sulkowska et al. [31] reported that mercury
evels in the cerebellar areas of the brain correlate with the oxida-
ive marker neurotrophin-3 (NT-3) in the brains of those with a
iagnosis of ASD. In contrast, Khan et al. [32] measured brain levels
f mercury and the oxidative stress marker, 3-nitrotyrosine (3-NT)
n both male and female control and ASD cases, age 4–16 years.
he researchers found that although 3-NT was increased in over-
ll ASD, mercury levels measured only in the extracortical regions
brain stem and cerebellum) were not different between cases and
ontrols (see Table 2 ). This ﬁnding may  suggest that the same lev-
ls of mercury may  promote oxidative stress only in susceptible
ndividuals.
Pamphlett and Kum Jew [33] examined the human locus
eruleus, a region of the brain that has been implicated in ASD. They
ound that controls were signiﬁcantly more likely to have mercury
n their locus ceruleus than the individuals with ASD. It is difﬁcult
o interpret the meaning of that ﬁnding, so that study was  catego-total mercury levels
osine; EEG = electroencephalogram; y = years of age.
rized as not showing a relationship between mercury and ASD and
placed in Table 2.
3. Human tissue mercury levels and ASD symptom severity
This section looks speciﬁcally at human tissue studies which
examine the relationship between mercury and symptom sever-
ity in ASD. In the studies that examine blood (whole blood and red
blood cells) and nails, results show that the higher the mercury lev-
els, the worse the autism symptoms. However, hair levels are not
simple to interpret. The ﬁrst study showing a relationship between
autism severity and hair mercury levels was published by Holmes
et al. [34]. They originally hypothesized that the higher the mercury
levels in the hair, the greater the autism severity (due to greater
exposure). However, they found that the more severely affected the
child was, the lower the hair mercury levels. When the researchers
found that hair mercury levels in the children with autism were
lower than controls (to be discussed more in the following section),
they proposed the “poor excretor theory” suggesting that children
with autism have more difﬁculty excreting mercury than typically
developing children and are more prone to accumulate the mer-
cury. Other studies, however, have found that the higher the hair
mercury concentrations, the worse the autism symptoms [35]. In
addition, evidence suggests that the time of hair growth analysis
is likely important because younger children with ASD show lower
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Table  2
Studies that did not show brain mercury levels were different in children with ASD vs. controls.
Biomarker Authors and Journal N Age Purpose of Study Findings
Brain Khan et al. [32]
J. Physiol. Pharmacol.
ASD 10
Controls 11
4–16 y
Brain mercury levels
measured in extracortical
regions autism vs. controls
Brain mercury levels
measured in extracortical
regions in children with
autism vs. controls were
not different
Brain-
Locus ceruleus
Pamphlett and Kum Jew
[33]
ASD 6
Controls 11
16–48 y
Levels on mercury in the
locus ceruleus
Higher levels of mercury
were found in the controls
ASD = autism spectrum disorders; y = years of age.
Table 3
Studies that show that human tissue mercury levels are associated with ASD symptom severity.
Body Tissue Authors and Journal N Age Purpose of Study Findings
Hair Holmes et al. [34]
Int J Toxicol
ASD 94
Controls 45
1–2 y
Relationship between autism
and hair mercury levels
Mercury levels inversely
correlated with symptom
severity
Hair  and nails Lakshmi Priya and Geetha [35]
Biol. Trace Elem. Res.
ASD 45
Controls 50
4–12 y
Lead and mercury in hair and
nails autism vs. controls
The elevation was much
pronounced in LFA group
subjects when compared
among autistic groups MFA
and HFA
Hair  Elsheshtawy et al. [37]
Middle East Curr. Psychiatry
ASD 32
Controls 32
Children
Investigated the relationship
between autism and mercury,
lead, copper, zinc
Positive correlation of CARS
scores with mercury from hair
samples
Hair  Geier et al. [38]
Int. J. Environ. Res. Public
Health
ASD 18
1–6 y
Hair toxic metal concentrations
and ASD severity
Increasing hair mercury
concentrations signiﬁcantly
correlated with increased ASD
severity
Whole blood and RBC Adams et al. [39]
Biol. Trace Elem. Res.
ASD 51
Controls 40
3–15 y
Investigated toxic metals in
autism and autism severity in
whole blood, RBCs, and urine
Found a strong association in
the degree of severity of
autism for all the severity
scales with mercury (whole
blood and RBC)
Red  Blood Cells (RBC) Alabdali et al. [40]
Behav. Brain Funct.
ASD 30
Controls 30
3–12 y
Concentration of lead and
mercury were measured in red
blood cells, plus GST and
vitamin E
Levels of mercury GST, and
vitamin E were correlated with
severity of social and cognitive
impairment measures
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[ST = glutathione-s-transferase; CARS = Childhood Autism Rating Scale; ASD = autism
ng  autism; MFA  = mid  functioning autism; HFA = high functioning autism; RBC = red
evels of hair mercury, while older children with ASD show higher
evels than their respective controls [36]. These ﬁndings suggest
wo competing variables: (1) susceptibility (poor excretors) and
2) exposure (higher exposure). Furthermore, these two  variables
ay  change over time, as detoxiﬁcation pathways become blocked
r cleared, and as exposures change, such that an absence of clear
ssociations between tissues levels and symptoms would be unsur-
rising. Nonetheless, based on the studies reviewed, some trends
an be observed. Table 3 lists human tissue (hair, nails, blood) stud-
es that show a correlation between tissue mercury levels and ASD
ymptom severity [34,35,37–40].
No studies were found during our literature search that exam-
ned tissue mercury levels and autism severity that did not ﬁnd a
orrelation. Thus, none are presented.
. Body tissues studies that examine mercury levels in ASD
s. controls
This section differs from the previous section because it does not
ddress symptom severity, but rather whether children with ASD
ave different levels of mercury in tissues than do control children.
he majority of studies ﬁnd differences in mercury levels between
hildren with ASD and healthy controls [34–37,40–52]. These stud-
es are presented in Table 4. However, many do not ﬁnd differences
56–63]. These studies are presented in Table 5 .trum disorders; ATEC = Autism Treatment Evaluation Checklist; LFA = low function-
d cells; y = years of age.
Worth noting is that the studies in Table 6 which compare the
mercury levels of children with ASD versus children with other neu-
rodevelopmental disorders show no differences in mercury levels
[64–66]. In many instances neurodevelopmental disorders are dif-
ﬁcult to clearly separate, because of frequent overlap in core and
associated features. This ﬁnding suggests that it is difﬁcult to sep-
arate these children based on biomarkers and/or xenobiotic levels
as well.
5. Porphyrin biomarkers of mercury body burden and ASD
severity
Studies have shown that urinary porphyrins (heme precursors
formed in the heme synthesis pathway) can afford a measure of
xenobiotic exposure and of tissue toxic metal body-burden, par-
ticularly with respect to mercury [67–69]. Mercury toxicity has
been demonstrated to be associated with elevations in urinary
coproporhyrin (cP), pentacoproporphyrin (5cxP), and an atypical
porphyrin, called precoprpophyrin (prcP) which is not found in the
urine of unexposed controls. As such, prcP is considered to be a spe-
ciﬁc porphyrin marker for mercury exposure [67–69], and elevated
urinary prcP is suggestive of mercury body burden [70]. The higher
the urinary prcp levels, the higher the mercury body burden.
Six of the seven studies in this section found a relationship
between the porphyrin biomarkers of mercury body burden and
ASD severity (Table 7 ) [63,61–76]. However, one did not ﬁnd a dif-
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Table 4
Human Tissue Studies that Show Signiﬁcantly Different Mercury Levels in ASD vs. Healthy Controls.
Body Tissue Authors and Journal N
Age
Purpose of Study Findings
Hair Holmes et al. [34]
Int. J. Toxicol.
ASD 94
Controls 45
1–2 y
Relationship between
autism and ﬁrst baby hair
mercury levels
The level of mercury was signiﬁcantly
lower in cases 0.47 ppm versus
3.63 ppm in controls
Hair  and nails Lakshmi Priya and Geetha [35]
Biol. Trace Elem. Res.
ASD 45
Controls 50
4–12 y
Lead and mercury in hair
and nails autism vs.
controls
Signiﬁcant elevation in the levels of
mercury in both hair and nail samples
in autism vs. controls
Hair  Majewska et al. [36]
Acta Neurobiol Exp
ASD 91
Controls 75
3–9 y
Levels of hair mercury in
autism vs. controls
Autistic children signiﬁcantly differed
from healthy peers in the
concentrations of mercury in hair
Hair  Elsheshtawy et al. [37]
Middle East Curr. Psychiatry
ASD 32
Controls 32
3–4 y
Investigated the
relationship between
autism and mercury, lead,
copper, zinc
The level of mercury was signiﬁcantly
lower in cases (0.55 ± 0.06 g/mg)
than in controls (3.2 ± 0.2 g/mg)
Hair  Mohamed et al. [41]
Behav. Neurol.
ASD 100
Controls 100
2–15 y
Assess the levels and
possible environmental
risk factors from metals
Hair mercury levels were higher in
children with ASD than controls
Hair  Tabatadze et al. [42]
Georgia Med. News
ASD 30
Controls 30
4–5 y
Evaluation levels of
essential trace elements
and heavy metals in ASD
vs. controls
High contamination to mercury in ASD
children compared to controls
Hair  Adams et al. [43]
Toxicol. Environ. Chem.
ASD 78
Controls 31
Born between 1988 and 99
First baby haircuts
evaluated for mercury and
ASD
Children with lower levels of mercury
in hair were 2.5 times more likely to
have ASD
Hair  DeSoto and Hitlan [44]
J. Child Neurol.
ASD 82
Controls 55
ASD mean 7.2 y
Controls mean 7.8 y
Examine mercury levels in
hair and blood
Signiﬁcant relation does exist between
the blood levels of mercury and ASD
with ASD having higher blood mercury
levels
Hair  Blaurock-Busch et al., [45]
Maedica (Buchar)
ASD 44
3–9 y
Assessed the levels of ten
toxic metals and essential
elements in hair samples of
children with autism
Elevated hair concentrations were
noted for mercury in autism vs.
controls
Hair  Hodgson et al. [46]
Exp. Biol. Med. (Maywood)
ASD 27
Controls 27
ASD mean 5.3 y Controls mean 5.5
y
Investigated hair mercury
levels in autism and
controls
Mercury levels were markedly
elevated in the hair of autistic subjects
vs. control subjects
Hair  Obrenovich et al. [47]
Biol. Trace Elem. Res.
ASD 22
Controls 39
<6 y
Hair toxic metals in autism
vs. controls
Signiﬁcant alteration in deposition of
several heavy metal species, including
mercury in hair samples between the
groups
Hair  Al-Ayadhi 2005 [48]
Neurosciences (Riyadh)
ASD 77
Controls 77
<14 y
Hair metals in autism vs.
controls
Higher levels of mercury in ASD vs.
controls
Hair  Fido and Al-Saad [49]
Autism
ASD 40
Controls 40
4–8 y
Toxic metals in the hair of
children with autism vs.
controls
Children with autism had signiﬁcantly
(p  < 0.001) higher in-hair concentration
levels of lead, mercury and uranium.
Blood and hair Yassa [50]
Environ. Toxicol. Pharmacol.
ASD 45
Controls 45
2–10 y
Blood and hair samples
from 45 children from
Upper Egypt with autism
vs. controls
High level of mercury and lead among
those kids with autism, with
signiﬁcant decline in the blood level of
lead and mercury with the use of
DMSA as a chelating agent
Red  Blood Cells (RBC) Alabdali et al. [40]
Behav. Brain. Funct.
ASD 20
Controls 20
3–15 y
Concentration of lead and
mercury were measured in
red blood cells, plus GST
and vitamin E
ASD had signiﬁcantly higher lead and
mercury levels and lower GST activity
and vitamin E concentrations
compared to controls
RBC  Geier et al. [51]
Acta Neurobiol. Exp. (Wars)
ASD 83
Controls 89
ASD mean 7.3 y
Controls mean 11.4 y
Mercury levels in children
with ASD vs. controls
Mean mercury levels were 1.9-fold
signiﬁcantly increased in ASD (21.4
microg/L) vs. controls (11.4 microg/L).
Blood  (plasma) El-Ansary [52]
Data in Brief
ASD 20
Controls 20
3–15 y
Mercury levels Blood mercury levels were higher in
ASD
Urine  Bradstreet et al. [53]
J. Am.  Phys. Surg.
ASD 221
Controls 18
3–16
Children with ASD and
controls treated with
multiple doses of DMSA
Children with ASD excreted six-fold
greater mercury than controls in their
urine
Urine  Blaurock-Busch et al. [54]
Maedica (Buchar)
ASD 44
Controls 146
3–9 y
Exposure to mercury and
other heavy metals in
children with autism
spectrum disorders versus
controls
Statistically signiﬁcant differences in
the mean urine levels of mercury
Baby  Teeth Adams et al.
J.  Toxicol. Environ. Health A [55]
ASD 15
Controls 11
4–9 y
Level of mercury, lead, and
zinc in baby teeth in
autism vs. controls
Children with autism had signiﬁcantly
(2.1-fold) higher levels of mercury
RBC+ red blood cells; GST = glutathione-s-transferase; DMSA = 2, 3-dimercaptosuccinic acid; y = years of age.
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Table  5
Body tissue studies that did not ﬁnd signiﬁcantly different mercury levels in ASD vs. healthy controls.
Type of Study Authors and Journal N
Age
Purpose of Study Findings
Hair De Palma et al. [56]
J. Aut. Dev. Disord.
ASD 44
Controls 61
Children
Hair toxic metals in autism vs.
controls
Found no association between
autism and hair mercury
Hair  and blood Ip et al. [57]
J. Child. Neurol.
ASD 82
Controls 55
ASD mean 7.2 y
Controls mean 7.8 y
Hair and blood mercury levels
and autism
No difference in the mean
mercury levels
Blood  Hertz-Picciotto et al. [58]
Environ. Health Perspect.
ASD 452
2–5 y
Blood mercury levels in autism
vs. controls
After accounting for dietary
and other differences in
mercury exposures, total
mercury in blood not
statistically different
Blood  Yau et al. [59]
Environ. Res.
ASD 84
Controls 159
<1 y
Prenatal and early-life
exposures to mercury
Total mercury in serum
collected from mothers during
mid-pregnancy and newborn
bloodspots were not
signiﬁcantly associated with
ASD
Blood  Rahbar et al. [60]
Neurotox. Res.
ASD 109
Controls 109
2–8 y
Investigate the association
between blood mercury
concentrations in control
children and ASDs
Did not ﬁnd a signiﬁcant
difference (P = 0.61) between
blood mercury concentrations
and ASDs
Blood/toxicokinetic model McKean et al. [61]
Environ. Health
ASD 164
DD 35
Controls 58
Mother infant pairs 274
<1 y
Using methyl-mercury
concentration estimates from
toxicokinetic model,
methyl-mercury exposure
estimated in autism, DD, and
controls
Cumulative methyl-mercury
exposure does not appear to
detectably elevate the risk of
autism or developmental delay
Urine  Soden et al. [62]
Clin. Toxicol. (Phila)
ASD 15
Controls 4
3–7 y
24-h provoked urine excretion
test for heavy metals in
children with autism
Excess chelatable body burden
of As, Cd, Pb, or mercury is zero
Urine  Woods et al. [63]
Environ. Health Perspect.
ASD 64
PDD 19
Controls 114
2–12 y
Mean mercury levels were
evaluated between autism,
PDD, and NT
No differences were found
between NT and autism in
urinary mercury levels or in
past mercury exposure
DD = developmental delay; NT = neurotypical; PDD = pervasive developmental disorder; As = arsenic; Cd = cadmium; Pb = lead; y = years of age.
Table 6
Body Tissue Studies that did not Find Signiﬁcantly Different Mercury Levels in ASD vs. Children with Neurological Disorders, Neuropsychiatric Disorders, or Learning
Disabilities.
Type of Study Authors and Journal N
Age
Purpose of Study Findings
Blood Macedoni-Luksˇicˇ et al. [64]
Biol. Trace Elem. Res.
ASD 52
Other neurologic disorders 22
1–16 y
Levels of metals in blood
aluminum, lead, mercury in
ASD compared to children with
neurological disorders
No signiﬁcant difference in
blood levels of metals between
the groups was found
Blood, urine and hair Albizzati et al. [65]
Przegl. Epidemiol.
ASD 17
Neuropsychiatric disorders 17
6–16 y
Metals in blood, urine and hair
samples from children with
autism and children with
neuropsychiatric disorders,
unspeciﬁed
No difference was found
between children with autism
and children with
neuropsychiatric disorders,
unspeciﬁed
Urine  Wright et al. [66]
PloS One
ASD 56
Siblings 42
Controls 121
Delayed 34
Urinary mercury levels
between children with ASD
and controls- normal and with
learning disabilities
No statistically signiﬁcant
differences were found
between children with ASD
and controls
A
f
A
6
s
t
A
A5–16 y
SD = autism spectrum disorders; y = years of age.
erence between the ASD cases and controls or a relationship with
SD severity (see Table 8 ) [77].
. Human tissue studies that show an increased
usceptibility to mercury (or “pro-oxidant environmental
oxins”) in ASDEarlier in Section 2, the issue of susceptibility to mercury in
SD was mentioned. Many studies suggest that children with
SD represent a population vulnerable to the adverse effectsof mercury [78]. This section covers studies which examine
susceptibility to mercury in ASD, listed in Table 9 . These
studies use a variety of tissues, including brain tissue, lym-
phoblastoid cell lines (LCLs), and blood samples [52,79–92]. A
major focus is the transmethylation/transsulfuration concentra-
tions, which are consistently found to be abnormal in ASD
[52,78,81–88,90]. Several of these studies suggest that children
with ASD have limited thiol availability and decreased glutathione
(GSH) reserve capacity, resulting in a compromised detoxiﬁca-
tion capacity and increased oxidative stress [52,78,81–88,90].
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Table 7
Studies that Show that Mercury Body Burden Biomarkers Correlate with ASD Severity.
Biomarker Authors and Journal N
Age
Purpose of Study Findings
Heme Synthesis Pathway
Metabolite
(precoproporphyrin)
Nataf et al. [71]
Toxicol. Appl. Pharmacol.
ASD 106
Controls 163
2–15 y
Examined urinary porphyrin
levels in children with
neurodevelopmental disorders
The atypical molecule
precoproporphyrin, a speciﬁc
indicator of heavy metal
toxicity, was also elevated in
autistic disorder but not
signiﬁcantly in Asperger’s
Heme Synthesis Pathway
Metabolite
(coproporphyrins)
Geier and Geier [72]
Neurotox. Res.
ASD 37
7–22 y
Examined urinary porphyrin
pattern indicative of mercury
toxicity
An apparent dose-response
effect was observed between
autism severity and increased
urinary coproporphyrins
Heme Synthesis Pathway
Metabolites
(pentacarboxyporphyrin,
precoproporphyrin, and
coproporphyrin)
Geier et al. [73]
J. Neurol. Sci.
ASD 26
2–13 y
Urinary porphyrins and
transsulfuration metabolites in
ASD were examined
Mercury
intoxication-associated urinary
porphyrins were signiﬁcantly
correlated with increasing
CARS scores and GSSG levels.
Heme  Synthesis Pathway
Metabolites
(coproporphyrins)
Geier et al. [74]
J. Toxicol. Environ. Health A
ASD 71
Controls 14
ASD 3–22 y
Controls 3–59 y
Evaluated relationship
between ASD severity and
urinary porphyrins
Participants with severe ASD
had signiﬁcantly increased cP I,
cP III, and total cP levels in
comparison to participants
with mild ASD. A signiﬁcant
correlation was  observed
between increasing cP levels
and CARS scores.
Heme  Synthesis Pathway
Metabolites
(pentacarboxyporphyrin,
precoproporphyrin, and
coproporphyrin)
Kern et al. [75]
Biometals
ASD 24
2–13 y
Urinary porphyrins and
speciﬁc domains of the ATEC
The results of the study
indicated that the overalll
ATEC scores and each of the
ATEC subscales
(Speech/Language, Sociability,
Sensory/Cognitive Awareness,
Health/Physical/Behavior)
were linearly related to urinary
porphyrins associated with
mercury toxicity.
Heme  Synthesis Pathway
Metabolite (pentacarboxyl
(penta) and coproporphyrins)
Heyer et al. [76]
Autism Res.
ASD 30
PDD 14
Controls 32
2–12 y
Evaluated penta and
coproporphyrins as biological
indicators of ASD, PDD-NOS,
neurotypical (NT) controls
ASD and PDD childrenhad
higher mean urinary penta and
copro-porphyrin
concentrations compared with
same-aged NT children.
Combined Z-score measure
had 33% and 21% sensitivity for
autism and PDD-NOS,
respectively, with 100%
speciﬁcity.
Heme Synthesis Pathway
Metabolite pentacarboxyl-,
precopro- and
copro-porphyrins
Woods et al. [63]
Environ. Health Perspect.
ASD 100
PDD 27
Controls 117
2–12 y
Mean porphyrin and mercury
levels were evaluated between
autism, PDD and NT
Elevated copro-, hexacarboxyl-
and pentacarboxyl- porphyrin
concentrations were associated
with autism but not PDD-NOS.
cP = coproporphyrin; cP I = coproporphyrin I; cP III = coproporphyrin III; penta = pentacarboxyl ASD = autism spectrum disorders; ATEC = Autism Treatment Evaluation Check-
list;  GSSG = oxidized glutathione; NT = neurotypical; PDD-NOS = pervasive developmental disorder −not otherwise speciﬁed; y = years of age.
Table 8
Studies that did not Show that Mercury Body Burden Biomarkers Correlate with ASD Severity.
Biomarker Authors and Journal N
Age
Purpose of Study Findings
Heme Synthesis Pathway
Metabolite
Shandley et al. [77]
Autism Res.
ASD 70
Siblings 36
Controls 54
2–6 y
Investigated whether
porphyrin proﬁles can reliably
be used to (a) differentiate ASD
cases from healthy controls;
and (b) predict ASD severity
Analyses did not to ﬁnd
support for the hypotheses
that porphyrin levels could
be used as a valid tool to
detect ASD cases or predict
A
F
s
A
b
s
c
[SD = autism spectrum disorders; y = years of age.
our of these studies are on brain tissue, showing increased
usceptibility to toxic substances in the brains of subjects with
SD. Most of these studies show susceptibility to mercury
ecause they show a suboptimal detoxiﬁcation capacity, however,
ome of the studies show direct evidence of increased mer-
ury damage in individuals with autism as compared to controls
79–81,89].severity
7. Epidemiological studies that examine Thimerosal in
vaccines as a risk factor for ASD
One of the most controversial areas of study is the epidemiolog-
ical investigation of mercury in Thimerosal – containing vaccines
(TCVs) as a risk factor for ASD. The controversial nature of these
studies is reﬂected by the fact that most of the studies that are
conducted without public health and/or industry support arrive
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Table 9
Tissue Studies that Examine Susceptibility to Mercury (or “pro-oxidant environmental toxins”) in ASD.
Body Tissue/Substance Authors and Journal N
Age
Purpose of Study Findings
LCLs Rose et al. [79]
J. Toxicol.
ASD 16
Controls 16
ASD 5–13 y
Controls 5–37 y
Human LCL in autism vs. controls exposed to TM Autism LCLs exhibited greater reduction in ATP-linked
respiration, maximal respiratory capacity, and reserve
capacity, compared to control LCLs exposed to TM
LCLs  Rose et al. [80]
Transl. Psychiatry
ASD 22
Controls 14
ASD mean 7.8 y
Controls mean 27.7 y
Human LCL in autism and mitochondrial reserve capacity Depletion of reserve capacity making them more
vulnerable to pro-oxidant environmental toxins
LCLs  James et al. [81]
FASEB J.
ASD 10
Controls 10
ASD mean 7.8 y
Controls mean 27.7 y
LCLs derived from autistic children and controls, effects of
TM on and GSH levels
TM resulted in greater decrease in GSH/GSSG ratio and
increase in free radical generation in autism vs. control
cells
Brain  Rose et al. [82]
Transl. Psychiatry
ASD 15
Controls 15
ASD 4–39 y
Controls 4–36 y
Examined cerebellum and temporal cortex (Brodmann
area 22 (BA22))
GSH was signiﬁcantly decreased in both the cerebellum
and BA22 in autism vs. controls; decreased GSH/GSSG
redox/antioxidant capacity and increased oxidative stress
in the autism brain
Cerebellum and temporal cortex Chauhan et al. [83]
Neurochem. Res.
ASD 10
Controls 10
4–39 y
Compared GSH redox status in postmortem brain samples
from cerebellum and frontal, temporal, parietal and
occipital cortex of subjects with ASD vs. controls
Levels of reduced GSH were signiﬁcantly decreased in
autism compared to controls: redox ratio of GSH to GSSG
was also signiﬁcantly decreased
Cerebellum Gu et al. [84]
Free Radic. Biol. Med.
ASD 10
Controls 10
ASD mean 11.1 y
Controls mean 11.3 y
Activities of GSH-related enzymes in the cerebellum
tissues from autism and controls
GPx, GST, GR, and GCL activity were signiﬁcantly decreased
in autism compared to that of the control group.
Plasma  Frye et al. [85]
Transl. Psychiatry
ASD 18
Controls 18
ASD mean 8.5 y
Controls mean 8.8 y
Plasma markers of oxidative stress and measures of
cognitive and language development and ASD behavior
ASD groups demonstrated lower fGSH and fGSH/GSSG
Plasma  Geier et al. [86]
J. Neurol. Sci.
ASD 28
2–16 y
Examined plasma transsulfuration metabolites Decreased plasma levels of reduced glutathione (GSH),
cysteine, and sulfate were observed among study
participants relative to controls
Plasma James et al. [87]
Am. J. Clin. Nutr.
ASD 40
Controls 42
2–7 y
Plasma concentrations of
transmethylation/transsulfuration metabolites and
glutathione redox status in autistic children
Transmethylation/transsulfuration pathway
concentrations in autistic children were signiﬁcantly
different from values in the control; and decreased
glutathione redox status in autism vs. controls
Plasma  James et al. [88]
Am. J. Med. Genet. B
Neuropsychiatr. Genet.
ASD 80
Controls 73
3–14 y
Plasma concentrations of
transmethylation/transsulfuration metabolites and
glutathione redox status in autistic children
Plasma levels of cysteine, glutathione, and the ratio of
reduced to oxidized glutathione, an indication of
antioxidant capacity and redox homeostasis, were
signiﬁcantly decreased
B-lymphocytes Sharpe et al. [89]
J. Toxicol.
ASD 4
Controls 4
5–13 y
TM exposure in B-lymphocytes taken from individuals
with autism, their nonautistic twins, and their nontwin
siblings
Exposure to TM resulted in four of the families showed
thimerosal hypersensitivity, whereas none of the control
individuals displayed this response
Peripheral blood mononuclear cells Rose et al. [90]
Autism Res. Treat.
ASD 43
Controls 41
3–10 y
Quantiﬁed the intracellular glutathione redox couple
(GSH/GSSG) in resting peripheral blood mononuclear cells
Both glutathione and cysteine redox ratios were decreased
in autistic compared to control children
Human  serum albumin Vojdani et al. [91]
Int. J. Immunopathol. Pharmacol.
ASD 50
Controls 50
3–14 y
Measured IgG, IgM and IgA antibodies against CD26, CD69,
streptokinase, gliadin and casein peptides and against
ethyl mercury bound to human serum albumin in autism
TM binds to lymphocyte receptors and/or tissue enzymes,
resulting in autoimmune reaction in children with autism
Blood  RNA, Gene Expression Stamova et al. [92]
Neurotox. Res.
ASD 33
Controls 51
2–5 y
Correlations between gene expression and mercury levels
in blood of boys with and without autism
Findings suggest different genetic transcriptional
programs associated with mercury levels in autism
compared to controls
Blood  (plasma) El-Ansary [52]
Data in Brief
ASD 20
Controls 20
3–15 y
Levels of GSH/GSSG Blood GSH levels were lower in ASD
LCL = lymphoblastoid cell lines; TM = Thimerosal; GSH = reduced glutathione; fGSH = reduced free glutathione; GSSG = oxidized glutathione; GPx = glutathione peroxidase; GST = glutathione-S-transferase; GR = glutathione reduc-
tase;  GCL = glutamate cysteine ligase; y = years of age.
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Table 10
Epidemiological studies that show thimerosal in vaccines is a risk factor for ASD.
Type of Study/Source of Exposure Authors and Journal Database
Age or Time Frame
Purpose of Study Findings
Epidemiology
TCVs
Gallagher and Goodman [93]
J. Toxicol. Environ. Health A
NHIS database
3–17 y
Examine NHIS 1997–2002, boys
3–17 years old, born before 1999
and exposure to TM
U.S. male neonates vaccinated
with the hepatitis B vaccine
prior to 1999 (from vaccination
record) had a threefold higher
risk for parental report of
autism diagnosis compared to
boys not vaccinated as
neonates during that same
time period
Epidemiology
TCVs
Gallagher and Goodman [94]
Toxicol. Environ. Chem.
NHANES database
1–9 y
Examine National Health and
Nutrition Examination Survey
1999–2000, children aged 1–9
years
Boys given Thimerosal (Hep B)
more susceptible to
developmental disability than
unvaccinated boys
Epidemiology
TCVs
Young et al. [95]
J. Neurosci.
VSD database
Birth to 13 months
Ecological study of TM containing
vaccines and risk of NDs
Increased risk of an ASD
diagnosis with TCVs
Epidemiology
TCVs
Geier  and Geier [96]
J. Toxicol. Environ. Health A
VAERS database
1994–1998
Dose (50 vs. 25 micrograms) of
mercury from TM in VAERS
Increased odds ratios for
autism with higher doses of TM
Epidemiology
TCVs
Geier  and Geier [97]
Med. Sci. Monit.
VAERS database
1997–2001
VSD database
1992–1997
Association between TCVs DTaP
comparison to TM-free DTaP and
autism in VAERS and VSD
Exposure to mercury from
TCVs administered in the US
was  a consistent signiﬁcant
risk factor for autism
Epidemiology
TCVs
Geier and Geier [98]
Pediatr. Rehabil.
VAERS database
USDE 2001
Dose of TCVs and autism in VAERS
and USDE data
Dose-response curves showed
increases in odds ratios of NDs
(autism) from both VAERS and
USDE closely linearly
correlated with increasing
doses of TM-containing
childhood vaccines
Epidemiology
TCVs
Geier  and Geier [99]
Exp. Biol. Med.
VAERS database
1992–2000
TM-DTaP and NDs in VAERS An association was found
between TM-DTaP and autism
Epidemiology
TCVs
Geier  and Geier [100]
Med. Sci. Monitor.
BSS-CDC database
USDE
CDC yearly live birth estimates
Mercury doses from TCVs on
population prevalence of autism
Evidence showing a direct
relationship between
increasing doses of mercury
from TCVs and autism
Epidemiology
TCVs
Geier  et al. [101]
Biol. Trace Elem. Res.
VSD database
PDD 534
PDD mean 4.1 y
Relationship between
Thimerosal-containing Hib and the
risk for PDD
Evidence supporting TCVs as a
risk factor for PDD
Epidemiology
TCVs
Geier et al. [102]
IJERPH
VSD database
1991–2000
NDs/PDD and Thimerosal dose Evidence supporting TCVs as a
risk factor for NDs/PDD that is
dose dependent
Epidemiology
TCVs
Geier et al. [104]
Transl. Neurodegener.
VAERS database
1998–2000
VSD database
1991–1999
Risk of ASD following TCVs Evidence supporting TCVs as a
risk factor for ASD
Epidemiology
TCVs
Geier et al. [104]
J. Biochem. Pharmacol. Res.
VAERS database
1997–1999
2004–2006
Risk of NDs following
Thimerosal-preserved DTaP
Evidence supporting TCVs as a
risk factor for NDs/PDD
HepB = Hepatitis B vaccine; TCVs = Thimerosal containing vaccines; ASD = autism spectrum disorders; PDD = pervasive developmental disorders; ND = neurodevelopmental
disorder; TM = Thimerosal; DTaP = Diphtheria, Tetanus, acellular Pertussis; HepB = Hepatitis B vaccine; Hib = Haemophilus inﬂuenzae Type b; RhoGAM = Rho (D) Immune
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tlobulin; VAERS = Vaccine Adverse Events Reporting System; VSD = Vaccine Safety
PA  = Environmental Protection Agency; RBC = red blood cells; DD = developmental 
nterview Survey; BSS-CDC = Biological Surveillance Summaries of the Centers for D
t conclusions that stand in sharp contrast to most of the studies
onducted or supported by public health entities and/or industry.
able 10 presents studies which ﬁnd Thimerosal in vaccines to be
 signiﬁcant risk factor for ASD [93–104]. Table 11 presents studies
hich ﬁnd Thimerosal in vaccines is not a signiﬁcant risk factor for
SD [105–112].
It should be mentioned, that Thimerosal was included in this
eview even though the mercury in Thimerosal is part of a
ompound: sodium ethyl-mercury thiosalicylate. This is because
himerosal is 49.55% mercury by weight and rapidly decomposes in
queous saline solutions into ethyl-mercury hydroxide and ethyl-
ercury chloride. Thimerosal is estimated to contribute to about
alf of the mercury exposure of infants [113]. Thimerosal is still
sed in many vaccines to date, particularly in developing countries
78].
It should also be mentioned that a review of the potential rela-
ionship between Thimerosal and ASD by Schultz [114] did notlink; USDE = US Department of Education; TCVs = Thimerosal-containing vaccines;
lity; NHANES = National Health and Nutrition Examination; NHIS = National Health
 Control; y = years of age.
include studies that used the VAERS database. Schultz stated that
the VAERS system is a passive reporting system to which anyone
can report and thus is a bias dataset. However, VAERS-based stud-
ies were included in this review because the Centers for Disease
Control (CDC) states that the reports of possible vaccine-associated
events to the VAERS are submitted by informed and conscientious
healthcare professionals and that despite the limitations of spon-
taneous reports, the VAERS database provides vital information of
clinical importance. The VAERS Working Group of the CDC and the
Food and Drug Administration (FDA) have published epidemiologic
studies based upon the VAERS [115].
8. Epidemiological studies that examine mercury in
RhoGam as a risk factor for ASD
Rho(D) immune globulin (Trade names include RhoGAM) is
given to a woman to prevent the formation of antibodies to Rh
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Table  11
Epidemiology Studies that did not Find a Relationship between Thimerosal in Vaccines is a Risk Factor for ASD.
Type of Study Source of
Exposure
Authors and Journal Database
Age or Time Frame
Purpose of Study Findings
Epidemiology
TCVs
Verstraeten et al. [105]
Pediatrics
VSD database
1991–1998
Assessed the possible toxicity
of TCVs among infants
No analyses found signiﬁcant
increased risks for autism
Epidemiology
TCVs
Madsen et al. [106]
Pediatrics
Danish Psychiatric Central
Research Register
2–10 y
TCVs in Denmark and
incidence of autism
Data do not support a
correlation between TCVs and
autism
Epidemiology
TCVs
Stehr-Green et al. [107]
Am. J. Pre. Med.
US – Special Education Services
Sweden – National database
Denmark- National registry
Mid  1980s – mid  1990s
TCVs and autism No correlation between TCVs
and autism
Epidemiology
TCVs
Hviid  et al. [108]
JAMA
Danish
National registry
1990–1996
To determine whether
vaccination with a
TM-containing vaccine is
associated with autism
Results do not support a causal
relationship between TCVs and
ASD
Epidemiology
TCVs
Andrews et al. [109]
Pediatrics
United Kingdom
National registry
1988–1997
Relationship between the
amount of TM an infant
receives via DTP or DT vaccine
and NDs (autism)
No evidence of an association
with TM exposure
Epidemiology
TCVs
Price  et al. [110]
Pediatrics
VSD
1994–1999
ASD 256
Controls 752
6–13 y
TCVs and autism No ﬁndings of increased risk for
any of the three ASD outcomes
Epidemiology
TCVs
Schechter and Grether [111]
Arch. Gen. Psychiatry
California Department of
Developmental Services
1995–2007
Autism prevalence in California
after removal of TM from most
childhood vaccines
Data do not support the
hypothesis that exposure to
TCVs during childhood is a
primary cause of autism
Epidemiology
TCVs
Mrozek-Budzyn et al. [112]
Przegl. Epidemiol.
Medical Records
ASD 96
Controls 193
Children
To determine an association of
TCVs exposure with the risk of
autism
No evidence of an association
between TCVs and autism
TCVs = Thimerosal containing vaccines; ASD = autism spectrum disorders; ND = neurodevelopmental disorder; TM = Thimerosal; DTaP = Diphtheria, Tetanus, acellular Pertus-
sis;  VSD = Vaccine Safety Datalink; y = years of age.
Table 12
Epidemiological Studies that Show Thimerosal in RhoGam is a Risk Factor for ASD.
Type of Study Source of
Exposure
Authors and Journal N Age or Time Frame Purpose of Study Findings
Epidemiology
RhoGAM
Geier et al. [116]
Neuro Endocrin. Lett.
NDs 298
Controls 124
Controls 2021
1980–2001
Controls 2002+
Maternal
Rh-negativity/TM-containing
RhoGAM
Increases in maternal
Rh-negativity among children
with NDs, autism spectrum
disorders, and attention-
deﬁcit-disorder/attention-
deﬁcit-hyperactivity-disorder
Epidemiology
RhoGAM
Geier  and Geier [117]
J. Matern. Fetal. Neonatal. Med.
ASD 53
Controls 926
ASD 1987–2001
Controls 1980–1989
Maternal
Rh-negativity/TM-containing
RhoGAM
Signiﬁcant dose-response
relationship between the
severity of the regressive ASDs
and total mercury dose
children received from
RhoGAM
RhoGAM = Rho (D) Immune Globulin; NDs = neurodevelopmental disorders.
Table 13
Epidemiological Studies that did not Show Thimerosal in RhoGam is a Risk Factor for ASD.
Type of Study Source of
Exposure
Authors and Journal N Age or Time Frame Purpose of Study Findings
Epidemiology
RhoGam
Miles and Takahashi [118]
Am. J. Med. Genet. A
ASD 214
Children diagnosed
-2005
Association between Rh status,
RhoGam use in pregnancy and
No association was found
between maternal RhoGam use
R
p
p
p
b
T
i
f
RhoGam manufacturer, Johnson and Johnson, Inc., did not ﬁnd
Thimerosal in RhoGam to be a risk factor for ASD [113]. In 2001,
Thimerosal was removed from Rh immune globulin [118].between1995
hoGAM = Rho (D) Immune Globulin.
ositive blood. It is an injection given at around 28 weeks of
regnancy to Rh negative mothers. For many years RhoGam was
reserved with Thimerosal. Three epidemiological studies have
een conducted to examine the safety of Rhogam preserved with
himerosal. Two studies (Table 12 ) conducted by independent
nvestigators, found Thimerosal in RhoGam to be a risk factor
or ASD [116,117]. The third study (Table 13 ), sponsored by theautism and autism
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Table 14
Epidemiological Studies that Show Mercury in Air Pollution is a Risk Factor for ASD.
Type of Study Source of
Exposure.
Authors and Journal N Age or Time Frame Purpose of Study Findings
Epidemiology
Prenatal Mercury Exposure
Zhang and Wong [119]
Environ. Int.
Total mercury emission based
on the data of 1999 in China
Examined mercury exposure
increases in China
Evidence suggests an increase
in autism related to increasing
mercury exposure
Epidemiology
Coal-burning power plants
Palmer et al. [120]
Health Place
Texas Education Department
2000–2001
EPA- Toxic Release Inventory
2004 4 million children
enrolled in grades K through 12
Mercury release, special
education rates, and autism
disorder
Association between
environmentally released
mercury and special education
rates were fully mediated by
increased autism rates.
Epidemiology
Coal-burning power plants
Palmer et al. [121]
Health Place
EPA-Toxic Release Inventory
1998
Proximity to mercury release
and autism prevalence
Association between
proximaty of released mercury
and autism
Epidemiology
Coal  burning power plants
Blanchard et al. [122]
Rev. Environ. Health
US EPA National Scale Air
Toxins
Assessment 2002
Texas Education Association
Occurrence of autism related to
distribution of mercury in
ambient air
Risk of autism is greater in the
geographic areas of higher
levels of ambient mercury
Epidemiology
Industrial facilities releasing
arsenic, lead or mercury into
air
Dickerson et al. [123]
Sci. Total Environ.
US EPA- Toxics Release
Inventory1991-1999
ADDM 2000–2008
ASD prevalence and proximity
to industrial facilities releasing
arsenic, lead or mercury
Association between urban
residential proximity to
industrial facilities emitting air
pollutants and higher ASD
prevalence
Epidemiology
Air  Pollution
Windham et al. [124]
Environ. Health Perspect.
HAP concentrations 1996
ASD 284
Controls 657
Born in 1994
ASD and environmental
exposures, ambient air, San
Francisco Bay
Increased risk of ASD
associations included mercury,
cadmium, nickel,
trichloroethylene, and vinyl
chloride
Epidemiology
Air  Pollution
Roberts et al. [125]
Environ. Health Perspect.
US EPA
Nurse’s Health Study II
ASD 325
Controls 22,101
Associations between U.S. EPA
– levels of hazardous air
pollutants at time and place of
birth and ASD
Overall measure of metals
were signiﬁcantly associated
with ASD, with odds ratios
ranging from 1.5 (for overall
metals measure) to 2.0 (for
diesel and mercury)
EPA = Environmental Protection Agency; ASD = autism spectrum disorders; ADDM = Autism and Developmental Disabilities Monitoring; HAP = hazardous air pollutant.
Table  15
Epidemiological studies that did not show mercury in air pollution is a risk factor for ASD.
Type of Study Source of
Exposure
Authors and Journal N
Age or Time Frame
Purpose of Study Findings
Epidemiology
Coal
Lewandowski et al. [126]
J. Toxicol. Environ. Health A
Texas Toxic Release Inventory
School District Autism
Prevalence
2001–2007
Mercury exposure from
coal-ﬁred power plants and
autism in Texas
Analysis suggests mercury
emissions not consistently
associated with autism
prevalence in Texas school
districts
Table 16
Epidemiological studies that show mercury from other sources is a risk factor for ASD.
Type of Study Source of
Exposure
Authors and Journal N
Age or Time Frame
Purpose of Study Findings
Epidemiology
mercury dental amalgams
Geier et al. [128]
Acta Neurobiol. Exp. (Wars)
ASD 100
7–13 y
Maternal dental amalgams
during pregnancy and risk of
autism
Subjects with > or = 6
amalgams were 3.2-fold
signiﬁcantly more likely to be
diagnosed with autism (severe)
in comparison to ASD (mild)
than subjects with < or = 5
amalgams.
Epidemiology
General/Pink Disease
Shandley and Austin [129]
J. Toxicol. Environ. Health
Australian Pink Disease
Support Group
2009
Tested the hypothesis that
individuals with a known
hypersensitivity to mercury
(pink disease survivors) may
be more likely to have
Prevalence rate of ASD among
the grandchildren of pink
disease survivors (1 in 22) to
be  signiﬁcantly higher than the
comparable general population
A
9
a
f
sSD = autism spectrum disorders; y = years of age.
. Epidemiological studies that examine mercury in the air
s a risk factor for ASDSeveral studies suggest that mercury in air pollution is a risk
actor for ASD, as shown in Table 14 [119–125]. The Palmer et al.
tudy [120] which found an association between mercury releasedescendants with an ASD prevalence rate (1 in 160).
and ASD rates was partially replicated by Lewandowski et al. [126];
however, Lewandowski and colleagues concluded that mercury
emissions were not consistently associated with autism prevalence
in Texas school districts, thus their study was placed in the category
of not ﬁnding a relationship between mercury and ASD (Table 15 ).
Overall, a 2014 meta-analysis of the evidence of the impact of pre-
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atal and early infancy mercury exposures on autism risk found
 signiﬁcant association between increasing environmental mer-
ury exposures and an increasing ASD risk (odds ratio = 1.66, 95%
onﬁdence interval = 1.14–2.17) [127]. It was observed that this
ffect remained similar after excluding studies not adjusted for con-
ounders . Table 16 presents studies that show mercury from other
ources is a risk factor for ASD.
0. Epidemiological studies that examine mercury from
ther sources as a risk factor for ASD
Geier et al. [128] found that maternal mercury ﬁllings during
regnancy were a risk factor for ASD. Austin and Shandley [129]
ypothesized and found that descendents of pink disease (mercury
oisoning) survivors would have a higher rate of ASD. In con-
rast, however, van Wijngaarden et al. [130] found no relationship
etween prenatal methyl-mercury exposure and ASD phenotypic
ehaviors (Table 17 ).
1. Discussion
As mentioned in the Introduction, numerous studies have been
onducted over the last three decades that examine the relationship
etween mercury and ASD. This comprehensive search for human
tudies that examined the potential relationship between mercury
nd ASD found 91 studies between 1999 to February 2016. The
ndings from the vast majority (74%) of those studies suggest that
ercury is a risk factor for ASD. These studies reveal both direct
nd indirect effects of mercury exposure. How these effects may
nteract in ASD is summarized in Fig. 1. Fig. 1 illustrates mercury
ffects on the brain in ASD as suggested by the research, show-
ng both causal and correlative ﬁndings. The ﬁgure shows, starting
rom the top, that mercury causes (purple arrows) autoimmune
ctivation, oxidative stress, neuroinﬂammation, neuronal damage,
nd loss of neuronal connectivity. These are direct effects from
ercury exposure. In the next line from the top, the ﬁgure shows
hat autoimmune activation, oxidative stress, neuroinﬂammation
an then also cause (purple arrows) neuronal damage and loss
f neuronal connectivity. These are indirect effects from mercury
xposure. The lower part of the ﬁgure shows the relevant correla-
ions (green arrows), such as autism symptom severity correlates
ith neuronal damage and neuronal loss of connectivity. In addi-
ion, autism symptom severity also correlates with mercury levels,
hich, in turn, correlate with autoimmune activation, oxidative
tress levels, and neuroinﬂammatory biomarkers.
1.1. Mercurial compounds and toxicity
Mercury exists in three forms: elemental mercury (e.g., vapor
rom dental amalgams), inorganic mercury compounds (e.g., mer-
uric chloride), and organic mercury compounds (e.g., methyl and
thyl mercury). According to the US Environmental Protection
gency, all forms of mercury are quite toxic [131]. Organic com-
ounds generally exert stronger cytotoxic effects as compared to
norganic mercury [132]. Methyl mercury can be formed by the
eaction of metallic mercury with organic molecules. Bacteria can
acilitate the formation of methyl mercury. An example of methyl
ercury poisoning is the Minamata tragedy where ﬁsh were
ontaminated with methyl mercury from the dumping of mercury-
ainted waste into water in Minamata, Japan. Exposed newborns
howed delayed neurodevelopmental toxicity [133]. Ethyl mer-
ury, which is used in Thimerosal (ethyl mercury thiosalicylate)
nd as a fungicide, is man-made. An example of ethyl mercury poi-
oning is the 1960 Iraq ethyl mercury tragedy where many familiesMedicine and Biology 37 (2016) 8–24 19
suffered illness and death from eating grains treated with ethyl
mercury [134].
Exposure to ethyl mercury is said to be safer than exposure to
methyl mercury because the blood half-life of intramuscular ethyl
mercury from Thimerosal in vaccines in infants has been found
to be substantially shorter than that of oral methyl mercury in
adults [135]. However, it is important to note that mercury from
Thimerosal is found in the brain and kidney and that even when
mercury levels are decreased in the blood, the mercury levels have
been found to be unchanged in the brain [136]. It is also important
to note that once the mercury from Thimerosal enters the brain,
some of it remains in the form of ethyl mercury, and some is found
as methyl mercury and inorganic mercury. As stated by Rodrigues
et al. [137], of the total mercury found in the brain after Thimerosal
exposure, 63% is in the form of inorganic mercury, 13.5% is ethyl
mercury, and 23.7% is methyl mercury. They further stated that
mercury in the tissues and blood following Thimerosal treatment
is predominantly found as inorganic mercury, but a considerable
amount of ethyl mercury is also found in the liver and brain.
Thimerosal is sometimes referred to as an adjuvant, a sub-
stance (as one added to a vaccine) that enhances the immune
response to an antigen [138]. More commonly, however, it is con-
sidered a preservative, while aluminum salts are considered the
most common adjuvant [139]. Both Thimerosal and aluminum are
considered xenobiotics and toxic, with Thimerosal being the more
toxic of the two  [140]. In the US Thimerosal is still in over 50%
of the ﬂu vaccines which are recommended for infants, children,
and pregnant women. It is also in tetanus and in one version of
the multidose meningococcal vaccine in the US. In the developing
countries around the world Thimerosal is still present in many of
the childhood vaccines [141].
11.2. Other neurotoxicants
Evidence suggests other possible causal or contributory expo-
sures, such as lead [35], organophosphate insecticides [142],
phthalates [143], glyphosates [144], and pyrethroids [145]. Expo-
sure to these other suggested xenobiotic exposures may  also be
causal and/or contributory in ASD; however, some research sug-
gests that their level of exposure and contribution may  conceivably
be less than mercury [146]. Future studies could include further
analysis of the attributable risk from neurotoxins.
11.3. Brain pathology and susceptibility
As mentioned in the Introduction, the brain pathology in ASD
indicates marked and ongoing inﬂammatory reactivity with con-
comitant neuronal damage. When brain inﬂammation is sustained,
as is seen in ASD, there is loss of neuronal connectivity, which is also
seen in ASD. It is conceivable that all of the suggested neurotoxi-
cants are able to bring about loss of connectivity through direct
insult as well as by activating a neuroinﬂammatory process from
which collateral damage is likely.
When the brain pathology in ASD is examined, it matches the
brain pathology found in mercury intoxication [18]. Kern et al.
[18] describe 20 different brain pathologies found in both ASD and
mercury intoxication. Lead and organophosphates have also been
shown to be capable of producing some of the same pathology
[147], although not as similar as that produced by mercury [18].
It is also important to mention that toxicants can work synergisti-
cally by depleting the sulfur dependent detoxiﬁcation system, and
glutathione reserves in particular.Many neurotoxicants, and particularly mercury, are sequestered
or detoxiﬁed by cellular thiols (organo-sulfur compound that con-
tains a carbon-bonded sulfhydryl ( C SH or R SH) group, such as
glutathione) and thiol availability is known to be limited in ASD
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Table 17
Epidemiological studies that did not show mercury from other sources is a risk factor for ASD.
Type of Study Source of
Exposure
Authors and Journal N
Age or Time Frame
Purpose of Study Findings
Epidemiology
Maternal
van Wijngaarden et al. [130]
Epidemiology
Seychelles Child Development
Study
1986–1990
Evaluated the association
between prenatal
methylmercury exposure and
ASD phenotype
Prenatal exposure to
methylmercury was not
associated with ASD
phenotypic behaviors
ASD = autism spectrum disorders.
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dFig. 1. This ﬁgure illustrates mercury effects on the brain in A
aking this population of individuals more susceptible to toxi-
ants. For example, Chauhan et al. [83] reported that in cerebellum
nd temporal cortex samples from subjects with ASD, glutathione
evels were signiﬁcantly decreased. Several other studies show that
hildren diagnosed with an ASD have abnormal sulfation chem-
stry, limited thiol availability, and decreased glutathione (GSH)
eserve capacity, with a resulting and subsequent compromised
xidation/reduction (redox) and detoxiﬁcation capacity [81,87,88]
nd a concomitant vulnerability to brain insult [78].
1.4. Neurodevelopmental disorders in general
The ﬁndings from this collection and review of the literature
n the relationship between ASD and mercury may  have broader
mplications. ASD has increased over the past three decades, but so
ave other neurodevelopmental disorders [148–156]. Some exam-
les are as follows: In the 1980s, 1 child in 1000 developed autism,
nd by 2013, 1 child in 45 developed autism [149–152]. In 1976,
 child in 30 was learning disabled, while by 2013, 1 child in 6
as learning disabled [148,149]. In 1996, 1 in 18 children devel-
ped attention deﬁcit/hyperactivity disorder (ADHD), and by 2012,
 in 8 children developed ADHD, an increase of about 75 percent
153]. The rate among children three to four years old with an ADHD
iagnosis has almost doubled since 1997 [153]. Tic disorder, once
onsidered rare, is now considered to be the most common move-
ent disorder, with 0.2-46.3% of school children experiencing tics
uring his/her lifetime [154]. Similarly, obsessive compulsive dis-ggested by the research, both causal and correlative ﬁndings.
order, also once considered rare, now affects at least 1 in 50–100
children depending on the estimates [155]. The needs and num-
bers of emotionally disturbed youth are also growing such that by
2004, about 1 in 11 children are were diagnosed with emotional
disturbances [156]. Overall, as of 2011, 1 in 6 children in the United
States had a neurodevelopmental disorder, which also represents
a dramatic increase in the last few decades [147,149].
11.5. Governmental policies and neurodevelopmental disorders
in general
It appears that lack of governmental intervention and regulation
may  be a contributing factor to the epidemic of neurodevelopmen-
tal disorders. Limited government action has taken place in regard
to reducing prenatal and postnatal exposure to mercury and other
neurotoxicants resulting in an ever increasingly toxic environment,
possibly due to conﬂict-of-interest issues and conﬂict between
areas of government. For example, the 2008 Obama/Biden Plan for
a Healthy America included the reduction of toxicants such as mer-
cury, stating that, “More than ﬁve million women of childbearing age
have high levels of toxic mercury in their blood, and approximately
630,000 newborns are born at risk every year.” However, in January
2012 when the US Food and Drug Administration (FDA) drafted a
rule prohibiting the use of mercury-based dental ﬁllings in preg-
nant women, nursing mothers, children aged less than 6 years of
age, and other sensitive groups, the United States Department of
nts in 
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ealth & Human Services (HHS), under President Obama, failed to
elease it [157,158]. As a consequence nothing was  accomplished.
2. Conclusion
The research that examines the relationship between mercury
nd ASD is extensive. One of the purposes of this review of the
cientiﬁc literature was to bring together and organize the plethora
f studies to make it easier for researchers to examine and interpret
he evidence. It is a compilation of every original study with any
nvestigation of ASD and any potential exposure to mercury from
ny source, at any time point, in the human population. In order
o limit the introduction of any bias, the authors of this review did
ot analyze each study, evaluate bias or study quality, or discuss
imilarities and difference between the studies.
From this inventory of the available research, it is clear that
he vast majority of the research, conducted by multiple research
roups, from many different countries, using many different
ethodologies, supports a link between mercury exposure and a
iagnosis of ASD. In this evaluation, it was found that 74% of studies
upport a link between mercury exposure and ASD, which corrobo-
ates a previous evaluation of the same issue conducted in 2010. In
hat study, Desoto and Hitlan also found that 74% of studies support
 link between mercury exposure and ASD [159]. This agreement
n science six years later is compelling and supports the validity of
he ﬁnding.
The compilation of the evidence indicates that children with ASD
re more susceptible to mercury than typically developing children,
nd that is reﬂected in signiﬁcantly different levels of mercury, or
iomarkers indicative of mercury, in the brain, blood, urine, baby
eeth, hair, and nails. In addition, many of these studies have found
hat the mercury, or biomarkers indicative of mercury, correlate
ith symptom severity such that the higher the mercury levels
he worse the autism symptom severity. The majority of the epi-
emiological research also support the hypothesis that mercury
s a risk factor for ASD. Based on the preponderance of the evi-
ence, mercury exposure is causal and/or contributory in ASD. With
he increase in neurodevelopmental disorders in general, and espe-
ially ASD, the evidence suggests that governmental/public policy
hanges are urgently needed.
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